Browse > Article
http://dx.doi.org/10.22722/KJPM.2018.26.2.112

Melatonin for Treatment of Delirium in Hospitalized Patients : Retrospective Trial  

Yang, Jung Woo (Department of Psychiatry, Kyung Hee University Hospital)
Kim, Jong Woo (Department of Psychiatry, Kyung Hee University Hospital)
Kang, Won Sub (Department of Psychiatry, Kyung Hee University Hospital)
Lee, Sang Min (Department of Psychiatry, Kyung Hee University Hospital)
Kim, Young Jong (Department of Psychiatry, Kyung Hee University Hospital)
Paik, Jong-Woo (Department of Psychiatry, Kyung Hee University Hospital)
Publication Information
Korean Journal of Psychosomatic Medicine / v.26, no.2, 2018 , pp. 112-118 More about this Journal
Abstract
Objectives : Delirium is one of the most common mental illnesses that can affect cognitive function. Melatonin has been shown to be effective in the treatment of insomnia, and recent studies have shown a protective effect to prevent delirium. This study was conducted to investigate the efficacy of melatonin in delirium patients. Methods : All patients were referred to psychiatric department for insomnia and symptoms of delirium, and were diagnosed delirium by the DSM-5 diagnostic criteria. We compared base line severity of delirium with K-DRS-R-98-R (Korean version of Delirium Rating Scale revised 98) and after taking 2mg of melatonin, retrospectively. The side effects were also identified by referring to the medical records. Results : A total 21 patients had taken melatonin for insomnia and delirious symptoms. The K-DRS-R-98 scores were decreased from $15.24{\pm}2.64$ before treatment to $6.57{\pm}5.42$ after treatment. And CGI-S scores were also decreased from $4.14{\pm}0.48$ before treatment to $2.81{\pm}0.93$ after treatment (p<0.05). Conclusions : This study illustrates the possibility of melatonin as an effective treatment option for delirious symptoms such as disorientation, motor agitation, lability of affect and hallucinations as well as insomnia, with less concerns of drug side effect. Further study with a larger sample and prospective design will be required to confirm these results.
Keywords
Delirium; Melatonin; Antipsychotics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Markowitz JD, Narasimhan M. Delirium and Antipsychotics: A Systematic Review of Epidemiology and Somatic Treatment Options. Psychiatry (Edgmont) 2008;5:29-36.
2 William B, Yesne A. Evidence-Based Treatment of Delirium in Patients With Cancer. J Clin Oncol 2012;30:11:1206-1214.   DOI
3 Gunther ML, Morandi A, Ely EW. Pathophysiology of delirium in the intensive care unit. Crit Care Clin 2008;24:45-65.   DOI
4 Hshieh TT, Fong TG, Marcantonio ER, Inouye SK. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci 2008;63:764-772.   DOI
5 Van Munster BC, Korevaar JC, Zwinderman AH, Levi M, Wiersinga WJ, De Rooij SE. Time course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc 2008;56:1704-1709.   DOI
6 Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythm: rationale for the development of specific melatonin agonist. Sleep Med 2004;5:523-532.   DOI
7 de Rooij SE, van Munster BC. Melatonin deficiency hypothesis in delirium: a synthesis of current evidence. Rejuvenation Res 2013;16:273-278.   DOI
8 Srinivasan V, Kaur C, Pandi-Perumal S, Brown GM, Cardinali DP. Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value. Int J Alzheimer's Dis 2011;741974.
9 Zhao LB, Zhen GD, Zhang Y, Pan YY, Du GH, Zhou SZ, Li ZF. Observation and analysis of clinical efficacy of melatonin on AOPP-induced delirium patients. Eur Rev Med Pharmacol Sci 2018;22:1494-1498.
10 Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick-DL, Reiter RJ, Efthimiopoulos S, Robakis NK. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997;17:1683-1690.   DOI
11 Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H. Preventive Effects of Ramelteon on Delirium A Randomized Placebo-Controlled Trial. JAMA Psychiatry 2014;71:397-403.   DOI
12 Balan S, Leibovitz A, Zila SO, Ruth M, Chana W, Yassica B, Rahel B, Richard G, Neumann E, Blagman B, Habot B. The relation between the clinical subtypes of delirium andthe urinary level of 6-SMT. J Neuropsychiatry Clin Neurosci 2003; 15:363-366.   DOI
13 Yoshitaka S, Egi M, Morimatsu H, Kanazawa T, Toda Y, Morita K. Perioperative plasma melatonin concentration in postoperative critically ill patients: its association with delirium. J Crit Care 2013;28:236-242.   DOI
14 Hanania M, Kitain E. Melatonin for treatment and prevention of postoperative delirium. Anesth Analg 2002;94:338-339.
15 Guy W. Clinical Global Impression(CGI) Modified From: Rush J, John A. Handbook of psychiatry Measures Washington, DC: American Psychiatric Association;2000. p.100-102.
16 Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci 2001;13:229-242.   DOI
17 Lee Y, Ryu J, Lee J, Kim HJ, Shin IH, Kim JL, Trzepacz PT. Korean version of the delirium rating scale-revised-98: reliability and validity. Psychiatry Investig 2011;8:30-38.   DOI
18 Lim KO, Kim SY, Lee YH, Lee SW, Kim JL. A validation study for the Korean version of Delirium Rating Scale-Revised-98 (K-DRS-98). J Korean Neuropsychiatr Assoc 2006;45: 518-526.
19 Witlox J, Eurelings LS, de Jonghe JF. Delirium in elderly patients and the risk of post discharge mortality, institutionalization, and dementia: a meta-analysis. JAMA Psychiatry 2010; 304:443-451.
20 Kimura R, Mori K, Kumazaki H, Yanagida M, Taguchi S, Matsunaga H. Treatment of delirium with ramelteon: Initial experience in three patients. Gen Hosp Psychiatry 2011;33: 407-409.   DOI
21 Furuya M, Miyaoka T, Yasuda H, Yamashita S, Tanaka I, Otsuka S, Wake R,Horiguchi J. Marked improvement in delirium with ramelteon: Five case reports. Psychogeriatrics 2012; 12:259-262.   DOI
22 Tsuda A, Nishimura K, Naganawa E, Otsubo T, Ishigooka J. Ramelteon for the treatment of delirium in elderly patients: a consecutive case series study. Int J Psychiatry Med 2014;47: 97-104.   DOI
23 Ohta T, Murao K, Miyake K, Takemoto K. Melatonin Receptor Agonists for Treating Delirium in Elderly Patients with Acute Stroke. J Stroke Cerebrovasc Dis 2013;22:1107-1110.   DOI
24 Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacologica Sinica 2006;27:41.   DOI
25 Miyaji S, Yamamoto K, Hoshino S, Yamamoto H, Sakai Y, Miyaoka H. Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. Psychiatry Clin Neurosci 2007;61:275-282.   DOI
26 Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341.   DOI
27 Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapinevs haloperidol: Treating delirium in a critical care setting. Intensive Care Med 2004;30:444-449.   DOI
28 Lee SJ, Jeong JH, Kim TW, Lim HK, Seo HJ, Hong SC, Han JH. Comparison of Treatment Response of Antipsychotics According to Sedative Effect in the Treatment of Patients with Delirium. Korean Journal of Psychopharmacology 2014; 25:168-174.
29 Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet 2014;383:911-922.   DOI
30 Cole M, McCusker J, Dendukuri N, Han L. The prognostic significance of subsyndromal delirium in elderly medical in patienrs. J Am Geriatr Soc 2003;51:754-760.   DOI
31 Cole MG. Delirium in elderly patients. Am J Geriatr Psychiatry 2004;12:7-21.   DOI
32 Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic Medication for Prevention and Treatment of Delirium in Hospitalized Adults: A Systematic Review and Meta-Analysis. J Am Geriatr Soc 2016;64:705-714.   DOI